Rajesh Khanna, Ph.D.
Richard And Thelma O.C. Barney Term Professor & Director, Center for Advanced Pain Therapeutics and Research (CAPToR)
Department:
MD-PHARMACOLOGY – THERAPEUTICS
Business Phone:
(520) 271-0433
Business Email:
r.khanna@ufl.edu
About Rajesh Khanna
Rajesh Khanna earned a Ph.D. in Physiology from the University of Toronto, Toronto, Canada where he also obtained his M.Sc. in Pharmacology and a B.Sc. in Toxicology. After completing a Natural Sciences and Engineering Research Council of Canada (NSERC)- and American Heart Association (AHA)-funded postdoctoral fellowship in Physiology and Molecular Biology at the University of California, Los Angeles, he completed a fellowship in Cellular and Molecular Biology at the Toronto Western Research Institute in Toronto, Ontario. Currently, he is the Director of Center for Advanced Pain Therapeutics and Research (CAPToR), University of Florida. Before his current role, he was an Assistant Professor at the Indiana University School of Medicine, a Professor at the University of Arizona, and a Professor and Director at NYU Pain Research Center (Molecular Pathobiology), New York University.
Additional Positions:
Director, Center for Advanced Pain Therapeutics and Research (CAPToR)
2024 – Current
·
University of Florida
Teaching Profile
Courses Taught
2025
GMS6560 Molecules to Man: Past, Present and Future Therapeutic Strategies for Disease
2025
GMS6009 Principles of Drug Action and Therapeutics
Research Profile
The Khanna lab studies allosteric regulation and trafficking of voltage-gated ion channels in chronic pain and neurodegenerative diseases. We are well-positioned to address broader foundational aspects of the chronification of pain, with multidisciplinary expertise in mouse genetics, confocal microscopy, protein biochemistry, electrophysiology – i.e. whole cell (current- and voltage-clamp; in rats, mice, pigs, macaque, and human DRGs) and slice (mice and rats), live imaging and evoked/affective pain behavioral analyses in rodent models to dissect mechanisms and roles of chronic pain.
Publications
Academic Articles
2025
Beyond single targets: leveraging degeneracy in sodium channels for osteoarthritis analgesia.
Pain reports.
10(4)
[DOI] 10.1097/PR9.0000000000001289.
[PMID] 40444024.
2025
Collapsin Response Mediator Protein 2 (CRMP2) Modulates Mitochondrial Oxidative Metabolism in Knock-In AD Mouse Model.
Cells.
14(9)
[DOI] 10.3390/cells14090647.
[PMID] 40358171.
2025
CRMP2 phosphorylation regulates polarization and spinal infiltration of CD4+ T lymphocytes, inhibits spinal glial activation, and arthritic pain.
Pain.
[DOI] 10.1097/j.pain.0000000000003599.
[PMID] 40258133.
2025
Evaluation of an indirect NaV1.7 inhibitor as adjunctive analgesic in burn-related neuropathic pain in a cat.
Veterinary anaesthesia and analgesia.
52(2):257-261
[DOI] 10.1016/j.vaa.2025.01.004.
[PMID] 39863517.
2025
Genetic editing of primary human dorsal root ganglion neurons using CRISPR-Cas9.
Scientific reports.
15(1)
[DOI] 10.1038/s41598-025-91153-2.
[PMID] 40169710.
2025
Mast cell chymases: essential for preventing the transition from acute to chronic pain.
Pain.
[DOI] 10.1097/j.pain.0000000000003566.
[PMID] 40146206.
2025
Pain’s puzzle pieces: MAGI-1, Na V 1.8, degradation, analgesia.
Pain.
166(5):972-974
[DOI] 10.1097/j.pain.0000000000003471.
[PMID] 39514286.
2025
Small molecule targeting NaV1.7 via inhibition of CRMP2-Ubc9 interaction reduces pain-related outcomes in a rodent osteoarthritic model
Pain.
166(1):99-111
[DOI] 10.1097/j.pain.0000000000003357.
[PMID] 39106443.
2025
SUMOylation and DeSUMOylation: Tug of War of Pain Signaling.
Molecular neurobiology.
62(3):3305-3321
[DOI] 10.1007/s12035-024-04478-w.
[PMID] 39276308.
2025
Targeting Nav1.7 and Nav1.8 with a PIKfyve inhibitor to reverse inflammatory and neuropathic pain.
Neurobiology of pain (Cambridge, Mass.).
17
[DOI] 10.1016/j.ynpai.2024.100174.
[PMID] 39720155.
2025
The conotoxin Contulakin-G reverses hypersensitivity observed in rodent models of cancer-induced bone pain without inducing tolerance or motor disturbance.
Pain.
166(2):376-387
[DOI] 10.1097/j.pain.0000000000003391.
[PMID] 39297754.
2025
The contribution of clock genes BMAL1 and PER2 in osteoarthritis-associated pain
Neurobiology of Pain.
17
[DOI] 10.1016/j.ynpai.2024.100177.
[PMID] 39850977.
2025
Unveiling the Dichotomic Nature of VEGFA in neuropathic pain: A path to targeted therapeutics.
Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics.
22(2)
[DOI] 10.1016/j.neurot.2025.e00534.
[PMID] 39864964.
2024
A parabrachial hub for the prioritization of survival behavior.
bioRxiv : the preprint server for biology.
[DOI] 10.1101/2024.02.26.582069.
[PMID] 38464066.
2024
C-H Functionalization-Enabled 11-Step Semisynthesis of (-)-Veragranine A and Characterization of Synthetic Analogs in Osteoarthritis-related Pain Treatment.
Journal of the American Chemical Society.
146(24):16698-705
[DOI] 10.1021/jacs.4c04025.
[PMID] 38843262.
2024
C2230, a preferential use- and state-dependent CaV2.2 channel blocker, mitigates pain behaviors across multiple pain models
Journal of Clinical Investigation.
135(4)
[DOI] 10.1172/jci177429.
2024
Corrigendum to “Evaluation of the effects of the T-type calcium channel enhancer SAK3 in a rat model of TAF1 deficiency” [Neurobiology of Disease 149 (2021) 105224].
Neurobiology of disease.
200
[DOI] 10.1016/j.nbd.2024.106620.
[PMID] 39097414.
2024
Effect of Crude Extract from the Sea Anemone Bunodeopsis globulifera on Voltage-Gated Ion Channels from Central and Peripheral Murine Nervous Systems
Pharmaceuticals.
17(8)
[DOI] 10.3390/ph17081006.
[PMID] 39204111.
2024
Green light exposure in children with autism spectrum disorder: a pilot study.
The Journal of clinical pediatric dentistry.
48(4):99-107
[DOI] 10.22514/jocpd.2024.083.
[PMID] 39087219.
2024
Human Hsp70 Substrate-Binding Domains Recognize Distinct Client Proteins.
Biochemistry.
63(3):251-263
[DOI] 10.1021/acs.biochem.3c00531.
[PMID] 38243804.
2024
Intranasal CRMP2-Ubc9 inhibitor regulates Na V 1.7 to alleviate trigeminal neuropathic pain.
Pain.
165(3):573-588
[DOI] 10.1097/j.pain.0000000000003053.
[PMID] 37751532.
2024
Mechanism, and treatment of anti-CV2/CRMP5 autoimmune pain.
bioRxiv : the preprint server for biology.
[DOI] 10.1101/2024.05.04.592533.
[PMID] 38766071.
2024
Mouse models of non-dystrophic and dystrophic myotonia exhibit nociplastic pain-like behaviors.
bioRxiv : the preprint server for biology.
[DOI] 10.1101/2024.06.19.599732.
[PMID] 38948724.
2024
Neuropeptide Y and Pain: Insights from Brain Research
ACS Pharmacology & Translational Science.
7(12):3718-3728
[DOI] 10.1021/acsptsci.4c00333.
[PMID] 39698268.
2024
Neuropilin-1 inhibition suppresses nerve growth factor signaling and nociception in pain models.
The Journal of clinical investigation.
135(4)
[DOI] 10.1172/JCI183873.
[PMID] 39589827.
2024
Neuropilin-1 is a co-receptor for Nerve Growth Factor-evoked pain.
bioRxiv : the preprint server for biology.
[DOI] 10.1101/2023.12.06.570398.
[PMID] 38106002.
2024
NF1+/ex42del miniswine model the cellular disruptions and behavioral presentations of NF1-associated cognitive and motor impairment.
Clinical and translational science.
17(6)
[DOI] 10.1111/cts.13858.
[PMID] 38932491.
2024
Nociplastic pain mechanisms and toll-like receptors as promising targets for its management.
Pain.
165(10):2150-2164
[DOI] 10.1097/j.pain.0000000000003238.
[PMID] 38595206.
2024
Peptide and Peptidomimetic Inhibitors Targeting the Interaction of Collapsin Response Mediator Protein 2 with the N-Type Calcium Channel for Pain Relief.
ACS pharmacology & translational science.
7(7):1916-1936
[DOI] 10.1021/acsptsci.4c00181.
[PMID] 39022365.
2024
Regulating neuronal excitability: The role of S-palmitoylation in NaV1.7 activity and voltage sensitivity.
PNAS nexus.
3(6)
[DOI] 10.1093/pnasnexus/pgae222.
[PMID] 38894876.
2024
STINGing away the pain: the role of interferon-stimulated genes.
The Journal of clinical investigation.
134(9)
[DOI] 10.1172/JCI180497.
[PMID] 38690736.
2024
Targeted transcriptional upregulation of SENP1 by CRISPR activation enhances deSUMOylation pathways to elicit antinociception in the spinal nerve ligation model of neuropathic pain.
Pain.
165(4):866-883
[DOI] 10.1097/j.pain.0000000000003080.
[PMID] 37862053.
2024
Uncoupling the CRMP2-CaV2.2 Interaction Reduces Pain-Like Behavior in a Preclinical Joint-Pain Model.
The journal of pain.
25(12)
[DOI] 10.1016/j.jpain.2024.104664.
[PMID] 39233208.
2024
Uncoupling the CRMP2-CaV2.2 interaction reduces pain-like behavior in a preclinical osteoarthritis model.
bioRxiv : the preprint server for biology.
[DOI] 10.1101/2024.06.05.596514.
[PMID] 38895294.
2023
A new polymodal gating model of the proton-activated chloride channel.
PLoS biology.
21(9)
[DOI] 10.1371/journal.pbio.3002309.
[PMID] 37713449.
2023
A peptidomimetic modulator of the CaV2.2 N-type calcium channel for chronic pain.
Proceedings of the National Academy of Sciences of the United States of America.
120(47)
[DOI] 10.1073/pnas.2305215120.
[PMID] 37972067.
2023
Argentatin C Analogues with Potential Antinociceptive Activity and Other Triterpenoid Constituents from the Aerial Parts of Parthenium incanum.
ACS omega.
8(22):20085-20095
[DOI] 10.1021/acsomega.3c02302.
[PMID] 37305315.
2023
Betulinic acid analogs inhibit N- and T-type voltage-gated calcium channels to attenuate nerve-injury associated neuropathic and formalin models of pain.
Neurobiology of pain (Cambridge, Mass.).
13
[DOI] 10.1016/j.ynpai.2023.100116.
[PMID] 36687466.
2023
Chronic pain recruits hypothalamic dynorphin/kappa opioid receptor signalling to promote wakefulness and vigilance.
Brain : a journal of neurology.
146(3):1186-1199
[DOI] 10.1093/brain/awac153.
[PMID] 35485490.
2023
CRMP2 Participates in Regulating Mitochondrial Morphology and Motility in Alzheimer’s Disease
Cells.
12(9)
[DOI] 10.3390/cells12091287.
[PMID] 37174687.
2023
Glutamatergic and GABAergic neurons in the vLGN mediate the nociceptive effects of green and red light on neuropathic pain.
Neurobiology of disease.
183
[DOI] 10.1016/j.nbd.2023.106164.
[PMID] 37217103.
2023
Identification and targeting of a unique NaV1.7 domain driving chronic pain.
Proceedings of the National Academy of Sciences of the United States of America.
120(32)
[DOI] 10.1073/pnas.2217800120.
[PMID] 37498871.
2023
Intranasal CRMP2-Ubc9 Inhibitor Regulates Na V 1.7 to Alleviate Trigeminal Neuropathic Pain.
bioRxiv : the preprint server for biology.
[DOI] 10.1101/2023.07.16.549195.
[PMID] 37502910.
2023
Neuropilin-1 is essential for vascular endothelial growth factor A-mediated increase of sensory neuron activity and development of pain-like behaviors.
Pain.
164(12):2696-2710
[DOI] 10.1097/j.pain.0000000000002970.
[PMID] 37366599.
2023
Some Like It Hot: Dynamic Control of Cav2.2 Channels By Chili Peppers.
Function (Oxford, England).
4(1)
[DOI] 10.1093/function/zqac066.
[PMID] 36632472.
2023
Targeting the vascular endothelial growth factor A/neuropilin 1 axis for relief of neuropathic pain.
Pain.
164(7):1473-1488
[DOI] 10.1097/j.pain.0000000000002850.
[PMID] 36729125.
2023
The Ca2+ channel ORAI1 is a regulator of oral cancer growth and nociceptive pain.
Science signaling.
16(801)
[DOI] 10.1126/scisignal.adf9535.
[PMID] 37669398.
2023
The Emerging Translational Potential of MNK Inhibitors for the Treatment of Chronic Pain.
Neuroscience.
515:93-95
[DOI] 10.1016/j.neuroscience.2023.02.009.
[PMID] 36922084.
2023
The natural product argentatin C attenuates postoperative pain via inhibition of voltage-gated sodium and T-type voltage-gated calcium channels.
British journal of pharmacology.
180(9):1267-1285
[DOI] 10.1111/bph.15974.
[PMID] 36245395.
2022
A prolactin-dependent sexually dimorphic mechanism of migraine chronification.
Cephalalgia : an international journal of headache.
42(3):197-208
[DOI] 10.1177/03331024211039813.
[PMID] 34510920.
2022
Alternaria alternata-induced airway epithelial signaling and inflammatory responses via protease-activated receptor-2 expression.
Biochemical and biophysical research communications.
591:13-19
[DOI] 10.1016/j.bbrc.2021.12.090.
[PMID] 34990903.
2022
Ca V 3.2 calcium channels: new players in facial pain.
Pain.
163(12):e1166-e1168
[DOI] 10.1097/j.pain.0000000000002652.
[PMID] 35442930.
2022
Cell specific regulation of NaV1.7 activity and trafficking in rat nodose ganglia neurons.
Neurobiology of pain (Cambridge, Mass.).
12
[DOI] 10.1016/j.ynpai.2022.100109.
[PMID] 36531612.
2022
Conditional knockout of CRMP2 in neurons, but not astrocytes, disrupts spinal nociceptive neurotransmission to control the initiation and maintenance of chronic neuropathic pain.
Pain.
163(2):e368-e381
[DOI] 10.1097/j.pain.0000000000002344.
[PMID] 35029600.
2022
Conotoxin contulakin-G engages a neurotensin receptor 2/R-type calcium channel (Cav2.3) pathway to mediate spinal antinociception.
Pain.
163(9):1751-1762
[DOI] 10.1097/j.pain.0000000000002561.
[PMID] 35050960.
2022
Dysregulation of serum prolactin links the hypothalamus with female nociceptors to promote migraine.
Brain : a journal of neurology.
145(8):2894-2909
[DOI] 10.1093/brain/awac104.
[PMID] 35325034.
2022
Effect of morphine and ibuprofen on nociceptive behavior, preening and motor activity following tonic chemical pain in the Japanese quail (Coturnix japonica).
Veterinary anaesthesia and analgesia.
49(5):499-509
[DOI] 10.1016/j.vaa.2022.07.001.
[PMID] 35961922.
2022
Heat shock protein Grp78/BiP/HspA5 binds directly to TDP-43 and mitigates toxicity associated with disease pathology.
Scientific reports.
12(1)
[DOI] 10.1038/s41598-022-12191-8.
[PMID] 35581326.
2022
Neurodegenerative Diseases: From Dysproteostasis, Altered Calcium Signalosome to Selective Neuronal Vulnerability to AAV-Mediated Gene Therapy.
International journal of molecular sciences.
23(22)
[DOI] 10.3390/ijms232214188.
[PMID] 36430666.
2022
Neuronal allodynic mechanisms of Slc7a5 (LAT1) in the spared nerve injury rodent model of neuropathic pain.
Pflugers Archiv : European journal of physiology.
474(4):397-403
[DOI] 10.1007/s00424-021-02653-9.
[PMID] 35048187.
2022
Neuronal CRMP2 phosphorylation inhibition by the flavonoid, naringenin, contributes to the reversal of spinal sensitization and arthritic pain improvement.
Arthritis research & therapy.
24(1)
[DOI] 10.1186/s13075-022-02975-8.
[PMID] 36564853.
2022
Plant and fungi derived analgesic natural products targeting voltage-gated sodium and calcium channels.
Channels (Austin, Tex.).
16(1):198-215
[DOI] 10.1080/19336950.2022.2103234.
[PMID] 36017978.
2022
Small molecule targeting NaV1.7 via inhibition of the CRMP2-Ubc9 interaction reduces and prevents pain chronification in a mouse model of oxaliplatin-induced neuropathic pain.
Neurobiology of pain (Cambridge, Mass.).
11
[DOI] 10.1016/j.ynpai.2021.100082.
[PMID] 35024498.
2022
Small molecule targeting NaV1.7 via inhibition of the CRMP2-Ubc9 interaction reduces pain in chronic constriction injury (CCI) rats.
Channels (Austin, Tex.).
16(1):1-8
[DOI] 10.1080/19336950.2021.2023383.
[PMID] 34983286.
2022
Stereospecific Effects of Benzimidazolonepiperidine Compounds on T-Type Ca2+ Channels and Pain.
ACS chemical neuroscience.
13(13):2035-2047
[DOI] 10.1021/acschemneuro.2c00256.
[PMID] 35671441.
2022
The small molecule compound C65780 alleviates pain by stabilizing voltage-gated sodium channels in the inactivated and slowly-recovering state.
Neuropharmacology.
212
[DOI] 10.1016/j.neuropharm.2022.109057.
[PMID] 35413303.
2022
Transmembrane protein TMEM184B is necessary for interleukin-31-induced itch.
Pain.
163(5):e642-e653
[DOI] 10.1097/j.pain.0000000000002452.
[PMID] 34629389.
2021
Comparison of quinazoline and benzoylpyrazoline chemotypes targeting the CaVα-β interaction as antagonists of the N-type CaV2.2 channel.
Channels (Austin, Tex.).
15(1):128-135
[DOI] 10.1080/19336950.2020.1863595.
[PMID] 33416017.
2021
CRMP2 Is Involved in Regulation of Mitochondrial Morphology and Motility in Neurons.
Cells.
10(10)
[DOI] 10.3390/cells10102781.
[PMID] 34685760.
2021
Evaluation of green light exposure on headache frequency and quality of life in migraine patients: A preliminary one-way cross-over clinical trial.
Cephalalgia : an international journal of headache.
41(2):135-147
[DOI] 10.1177/0333102420956711.
[PMID] 32903062.
2021
Evaluation of the effects of the T-type calcium channel enhancer SAK3 in a rat model of TAF1 deficiency.
Neurobiology of disease.
149
[DOI] 10.1016/j.nbd.2020.105224.
[PMID] 33359140.
2021
Green Light Antinociceptive and Reversal of Thermal and Mechanical Hypersensitivity Effects Rely on Endogenous Opioid System Stimulation.
The journal of pain.
22(12):1646-1656
[DOI] 10.1016/j.jpain.2021.05.006.
[PMID] 34157406.
2021
Green Light Exposure Improves Pain and Quality of Life in Fibromyalgia Patients: A Preliminary One-Way Crossover Clinical Trial.
Pain medicine (Malden, Mass.).
22(1):118-130
[DOI] 10.1093/pm/pnaa329.
[PMID] 33155057.
2021
Inhibition of autophagy by CRMP2-derived peptide ST2-104 (R9-CBD3) via a CaMKKβ/AMPK/mTOR pathway contributes to ischemic postconditioning-induced neuroprotection against cerebral ischemia-reperfusion injury.
Molecular brain.
14(1)
[DOI] 10.1186/s13041-021-00836-0.
[PMID] 34362425.
2021
Intellectual disability: dendritic anomalies and emerging genetic perspectives.
Acta neuropathologica.
141(2):139-158
[DOI] 10.1007/s00401-020-02244-5.
[PMID] 33226471.
2021
Involvement of CRMP2 in Regulation of Mitochondrial Morphology and Motility in Huntington’s Disease.
Cells.
10(11)
[DOI] 10.3390/cells10113172.
[PMID] 34831395.
2021
L5-6 Spinal Nerve Ligation-induced Neuropathy Changes the Location and Function of Ca2+ Channels and Cdk5 and Affects the Compound Action Potential in Adjacent Intact L4 Afferent Fibers.
Neuroscience.
471:20-31
[DOI] 10.1016/j.neuroscience.2021.07.013.
[PMID] 34303780.
2021
Missense variants in DPYSL5 cause a neurodevelopmental disorder with corpus callosum agenesis and cerebellar abnormalities.
American journal of human genetics.
108(5):951-961
[DOI] 10.1016/j.ajhg.2021.04.004.
[PMID] 33894126.
2021
Non-SUMOylated CRMP2 decreases NaV1.7 currents via the endocytic proteins Numb, Nedd4-2 and Eps15.
Molecular brain.
14(1)
[DOI] 10.1186/s13041-020-00714-1.
[PMID] 33478555.
2021
Novel Compounds Targeting Neuropilin Receptor 1 with Potential To Interfere with SARS-CoV-2 Virus Entry.
ACS chemical neuroscience.
12(8):1299-1312
[DOI] 10.1021/acschemneuro.0c00619.
[PMID] 33787218.
2021
SARS-CoV-2 spike protein co-opts VEGF-A/neuropilin-1 receptor signaling to induce analgesia.
Pain.
162(1):243-252
[DOI] 10.1097/j.pain.0000000000002097.
[PMID] 33009246.
2021
Selective targeting of NaV1.7 via inhibition of the CRMP2-Ubc9 interaction reduces pain in rodents.
Science translational medicine.
13(619)
[DOI] 10.1126/scitranslmed.abh1314.
[PMID] 34757807.
2021
Targeting T-type/CaV3.2 channels for chronic pain.
Translational research : the journal of laboratory and clinical medicine.
234:20-30
[DOI] 10.1016/j.trsl.2021.01.002.
[PMID] 33422652.
2021
The Effects of Repeated Morphine Treatment on the Endogenous Cannabinoid System in the Ventral Tegmental Area.
Frontiers in pharmacology.
12
[DOI] 10.3389/fphar.2021.632757.
[PMID] 33953672.
2020
1-O-Acetylgeopyxin A, a derivative of a fungal metabolite, blocks tetrodotoxin-sensitive voltage-gated sodium, calcium channels and neuronal excitability which correlates with inhibition of neuropathic pain.
Molecular brain.
13(1)
[DOI] 10.1186/s13041-020-00616-2.
[PMID] 32393368.
2020
A modulator of the low-voltage-activated T-type calcium channel that reverses HIV glycoprotein 120-, paclitaxel-, and spinal nerve ligation-induced peripheral neuropathies.
Pain.
161(11):2551-2570
[DOI] 10.1097/j.pain.0000000000001955.
[PMID] 32541387.
2020
Collapsin Response Mediator Proteins: Novel Targets for Alzheimer’s Disease.
Journal of Alzheimer's disease : JAD.
77(3):949-960
[DOI] 10.3233/JAD-200721.
[PMID] 32804096.
2020
Coordinating Synaptic Signaling with CRMP2.
The international journal of biochemistry & cell biology.
124
[DOI] 10.1016/j.biocel.2020.105759.
[PMID] 32437854.
2020
Differential expression of Cdk5-phosphorylated CRMP2 following a spared nerve injury.
Molecular brain.
13(1)
[DOI] 10.1186/s13041-020-00633-1.
[PMID] 32571373.
2020
Druggability of CRMP2 for Neurodegenerative Diseases.
ACS chemical neuroscience.
11(17):2492-2505
[DOI] 10.1021/acschemneuro.0c00307.
[PMID] 32693579.
2020
Dynamic CRMP2 Regulation of CaV2.2 in the Prefrontal Cortex Contributes to the Reinstatement of Cocaine Seeking.
Molecular neurobiology.
57(1):346-357
[DOI] 10.1007/s12035-019-01711-9.
[PMID] 31359322.
2020
In silico identification and validation of inhibitors of the interaction between neuropilin receptor 1 and SARS-CoV-2 Spike protein.
bioRxiv : the preprint server for biology.
[DOI] 10.1101/2020.09.22.308783.
[PMID] 32995772.
2020
Just in time! Identification of a novel mechanism for treating PIPN.
The Journal of physiology.
598(12):2283-2284
[DOI] 10.1113/JP279863.
[PMID] 32266977.
2020
Longitudinal phenotype development in a minipig model of neurofibromatosis type 1.
Scientific reports.
10(1)
[DOI] 10.1038/s41598-020-61251-4.
[PMID] 32193437.
2020
Mutant huntingtin does not cross the mitochondrial outer membrane.
Human molecular genetics.
29(17):2962-2975
[DOI] 10.1093/hmg/ddaa185.
[PMID] 32821928.
2020
Nasal delivery of a CRMP2-derived CBD3 adenovirus improves cognitive function and pathology in APP/PS1 transgenic mice.
Molecular brain.
13(1)
[DOI] 10.1186/s13041-020-00596-3.
[PMID] 32272942.
2020
Putative roles of SLC7A5 (LAT1) transporter in pain.
Neurobiology of pain (Cambridge, Mass.).
8
[DOI] 10.1016/j.ynpai.2020.100050.
[PMID] 32715162.
2020
SARS-CoV-2 Spike protein co-opts VEGF-A/Neuropilin-1 receptor signaling to induce analgesia.
bioRxiv : the preprint server for biology.
[DOI] 10.1101/2020.07.17.209288.
[PMID] 32869019.
2020
Sculpting Dendritic Spines during Initiation and Maintenance of Neuropathic Pain.
The Journal of neuroscience : the official journal of the Society for Neuroscience.
40(40):7578-7589
[DOI] 10.1523/JNEUROSCI.1664-20.2020.
[PMID] 32998955.
2020
Studies on CRMP2 SUMOylation-deficient transgenic mice identify sex-specific Nav1.7 regulation in the pathogenesis of chronic neuropathic pain.
Pain.
161(11):2629-2651
[DOI] 10.1097/j.pain.0000000000001951.
[PMID] 32569093.
2020
Synaptic zinc inhibition of NMDA receptors depends on the association of GluN2A with the zinc transporter ZnT1.
Science advances.
6(27)
[DOI] 10.1126/sciadv.abb1515.
[PMID] 32937457.
2020
Targeted disruption of Kv2.1-VAPA association provides neuroprotection against ischemic stroke in mice by declustering Kv2.1 channels.
Science advances.
6(27)
[DOI] 10.1126/sciadv.aaz8110.
[PMID] 32937450.
2020
The investigation of the T-type calcium channel enhancer SAK3 in an animal model of TAF1 intellectual disability syndrome.
Neurobiology of disease.
143
[DOI] 10.1016/j.nbd.2020.105006.
[PMID] 32622085.
2020
The prolactin receptor long isoform regulates nociceptor sensitization and opioid-induced hyperalgesia selectively in females.
Science translational medicine.
12(529)
[DOI] 10.1126/scitranslmed.aay7550.
[PMID] 32024801.
2020
The role of cyclin-dependent kinase 5 in neuropathic pain.
Pain.
161(12):2674-2689
[DOI] 10.1097/j.pain.0000000000002027.
[PMID] 32773603.
2020
The Septum-Hippocampal Cholinergic Circuit: A Novel Pathway for Seizure Control.
Biological psychiatry.
87(9):785-786
[DOI] 10.1016/j.biopsych.2020.02.003.
[PMID] 32299581.
2020
Validating indicators of CNS disorders in a swine model of neurological disease.
PloS one.
15(2)
[DOI] 10.1371/journal.pone.0228222.
[PMID] 32074109.
2019
(-)-Hardwickiic Acid and Hautriwaic Acid Induce Antinociception via Blockade of Tetrodotoxin-Sensitive Voltage-Dependent Sodium Channels.
ACS chemical neuroscience.
10(3):1716-1728
[DOI] 10.1021/acschemneuro.8b00617.
[PMID] 30525440.
2019
AAV-encoded CaV2.2 peptide aptamer CBD3A6K for primary sensory neuron-targeted treatment of established neuropathic pain.
Gene therapy.
26(7-8):308-323
[DOI] 10.1038/s41434-019-0082-7.
[PMID] 31118475.
2019
Activity of T-type calcium channels is independent of CRMP2 in sensory neurons.
Channels (Austin, Tex.).
13(1):147-152
[DOI] 10.1080/19336950.2019.1608129.
[PMID] 31025580.
2019
Assessment of nociception and related quality-of-life measures in a porcine model of neurofibromatosis type 1.
Pain.
160(11):2473-2486
[DOI] 10.1097/j.pain.0000000000001648.
[PMID] 31246731.
2019
Betulinic acid, derived from the desert lavender Hyptis emoryi, attenuates paclitaxel-, HIV-, and nerve injury-associated peripheral sensory neuropathy via block of N- and T-type calcium channels.
Pain.
160(1):117-135
[DOI] 10.1097/j.pain.0000000000001385.
[PMID] 30169422.
2019
Cdk5-mediated CRMP2 phosphorylation is necessary and sufficient for peripheral neuropathic pain.
Neurobiology of pain (Cambridge, Mass.).
5
[DOI] 10.1016/j.ynpai.2018.07.003.
[PMID] 31080913.
2019
CRMP2-derived peptide ST2-104 (R9-CBD3) protects SH-SY5Y neuroblastoma cells against Aβ25-35-induced neurotoxicity by inhibiting the pCRMP2/NMDAR2B signaling pathway.
Chemico-biological interactions.
305:28-39
[DOI] 10.1016/j.cbi.2019.03.005.
[PMID] 30871964.
2019
Defining the Kv2.1-syntaxin molecular interaction identifies a first-in-class small molecule neuroprotectant.
Proceedings of the National Academy of Sciences of the United States of America.
116(31):15696-15705
[DOI] 10.1073/pnas.1903401116.
[PMID] 31308225.
2019
Development and Characterization of An Injury-free Model of Functional Pain in Rats by Exposure to Red Light.
The journal of pain.
20(11):1293-1306
[DOI] 10.1016/j.jpain.2019.04.008.
[PMID] 31054915.
2019
Discovery of Quinoline Analogues as Potent Antivirals against Enterovirus D68 (EV-D68).
Journal of medicinal chemistry.
62(8):4074-4090
[DOI] 10.1021/acs.jmedchem.9b00115.
[PMID] 30912944.
2019
Dysregulation of CRMP2 Post-Translational Modifications Drive Its Pathological Functions.
Molecular neurobiology.
56(10):6736-6755
[DOI] 10.1007/s12035-019-1568-4.
[PMID] 30915713.
2019
Erratum to ‛Development and Characterization of An Injury-free Model of Functional Pain in Rats by Exposure to Red Light’: The Journal of Pain 20 (2019) 1293-1306.
The journal of pain.
20(12)
[DOI] 10.1016/j.jpain.2019.11.012.
[PMID] 31818395.
2019
Evaluation of edonerpic maleate as a CRMP2 inhibitor for pain relief.
Channels (Austin, Tex.).
13(1):498-504
[DOI] 10.1080/19336950.2019.1684608.
[PMID] 31680630.
2019
Mining the Nav1.7 interactome: Opportunities for chronic pain therapeutics.
Biochemical pharmacology.
163:9-20
[DOI] 10.1016/j.bcp.2019.01.018.
[PMID] 30699328.
2019
Modulation of CRMP2 via (S)-Lacosamide shows therapeutic promise but is ultimately ineffective in a mouse model of CLN6-Batten disease.
Neuronal signaling.
3(2)
[DOI] 10.1042/NS20190001.
[PMID] 32269836.
2019
Neuronal Conditional Knockout of Collapsin Response Mediator Protein 2 Ameliorates Disease Severity in a Mouse Model of Multiple Sclerosis
ASN Neuro.
11(1)
[DOI] 10.1177/1759091419892090.
[PMID] 31795726.
2019
Phosphorylated CRMP2 Regulates Spinal Nociceptive Neurotransmission.
Molecular neurobiology.
56(7):5241-5255
[DOI] 10.1007/s12035-018-1445-6.
[PMID] 30565051.
2019
Reversal of Peripheral Neuropathic Pain by the Small-Molecule Natural Product Physalin F via Block of CaV2.3 (R-Type) and CaV2.2 (N-Type) Voltage-Gated Calcium Channels.
ACS chemical neuroscience.
10(6):2939-2955
[DOI] 10.1021/acschemneuro.9b00166.
[PMID] 30946560.
2019
Small Molecule Targeting TDP-43’s RNA Recognition Motifs Reduces Locomotor Defects in a Drosophila Model of Amyotrophic Lateral Sclerosis (ALS).
ACS chemical biology.
14(9):2006-2013
[DOI] 10.1021/acschembio.9b00481.
[PMID] 31241884.
2019
TAF1-gene editing alters the morphology and function of the cerebellum and cerebral cortex.
Neurobiology of disease.
132
[DOI] 10.1016/j.nbd.2019.104539.
[PMID] 31344492.
2019
Targeting the CaVα-CaVβ interaction yields an antagonist of the N-type CaV2.2 channel with broad antinociceptive efficacy.
Pain.
160(7):1644-1661
[DOI] 10.1097/j.pain.0000000000001524.
[PMID] 30933958.
2019
Tetramethylpyrazine Reduces Epileptogenesis Progression in Electrical Kindling Models by Modulating Hippocampal Excitatory Neurotransmission.
ACS chemical neuroscience.
10(12):4854-4863
[DOI] 10.1021/acschemneuro.9b00575.
[PMID] 31756074.
2019
The Natural Flavonoid Naringenin Elicits Analgesia through Inhibition of NaV1.8 Voltage-Gated Sodium Channels.
ACS chemical neuroscience.
10(12):4834-4846
[DOI] 10.1021/acschemneuro.9b00547.
[PMID] 31697467.
2019
TNF-α mediated upregulation of NaV1.7 currents in rat dorsal root ganglion neurons is independent of CRMP2 SUMOylation.
Molecular brain.
12(1)
[DOI] 10.1186/s13041-019-0538-0.
[PMID] 31888677.
2019
Towards a neurobiological understanding of pain in neurofibromatosis type 1: mechanisms and implications for treatment.
Pain.
160(5):1007-1018
[DOI] 10.1097/j.pain.0000000000001486.
[PMID] 31009417.
2018
A Chemical Biology Approach to Model Pontocerebellar Hypoplasia Type 1B (PCH1B).
ACS chemical biology.
13(10):3000-3010
[DOI] 10.1021/acschembio.8b00745.
[PMID] 30141626.
2018
A light-gated potassium channel for sustained neuronal inhibition.
Nature methods.
15(11):969-976
[DOI] 10.1038/s41592-018-0186-9.
[PMID] 30377377.
2018
A novel variant in TAF1 affects gene expression and is associated with X-linked TAF1 intellectual disability syndrome.
Neuronal signaling.
2(3)
[DOI] 10.1042/NS20180141.
[PMID] 32714589.
2018
A porcine model of neurofibromatosis type 1 that mimics the human disease.
JCI insight.
3(12)
[DOI] 10.1172/jci.insight.120402.
[PMID] 29925695.
2018
Chemical shift perturbation mapping of the Ubc9-CRMP2 interface identifies a pocket in CRMP2 amenable for allosteric modulation of Nav1.7 channels.
Channels (Austin, Tex.).
12(1):219-227
[DOI] 10.1080/19336950.2018.1491244.
[PMID] 30081699.
2018
CRMP2 and voltage-gated ion channels: potential roles in neuropathic pain.
Neuronal signaling.
2(1)
[DOI] 10.1042/NS20170220.
[PMID] 30364788.
2018
CRMP2 is necessary for Neurofibromatosis type 1 related pain.
Channels (Austin, Tex.).
12(1):47-50
[DOI] 10.1080/19336950.2017.1370524.
[PMID] 28837387.
2018
CRMP2 Phosphorylation Drives Glioblastoma Cell Proliferation.
Molecular neurobiology.
55(5):4403-4416
[DOI] 10.1007/s12035-017-0653-9.
[PMID] 28660485.
2018
CRMP2-Neurofibromin Interface Drives NF1-related Pain.
Neuroscience.
381:79-90
[DOI] 10.1016/j.neuroscience.2018.04.002.
[PMID] 29655575.
2018
High Fidelity Cryopreservation and Recovery of Primary Rodent Cortical Neurons.
eNeuro.
5(5)
[DOI] 10.1523/ENEURO.0135-18.2018.
[PMID] 30263951.
2018
Homology-guided mutational analysis reveals the functional requirements for antinociceptive specificity of collapsin response mediator protein 2-derived peptides.
British journal of pharmacology.
175(12):2244-2260
[DOI] 10.1111/bph.13737.
[PMID] 28161890.
2018
In Reply.
Anesthesiology.
129(2):378-379
[DOI] 10.1097/ALN.0000000000002294.
[PMID] 30020181.
2018
Inhibition of the Ubc9 E2 SUMO-conjugating enzyme-CRMP2 interaction decreases NaV1.7 currents and reverses experimental neuropathic pain.
Pain.
159(10):2115-2127
[DOI] 10.1097/j.pain.0000000000001294.
[PMID] 29847471.
2018
Restoration of Kv7 Channel-Mediated Inhibition Reduces Cued-Reinstatement of Cocaine Seeking.
The Journal of neuroscience : the official journal of the Society for Neuroscience.
38(17):4212-4229
[DOI] 10.1523/JNEUROSCI.2767-17.2018.
[PMID] 29636392.
2018
Unconventional Signaling by Extracellular CRMP2: Possible Role as an Atypical Neurotransmitter?
Neuroscience.
376:224-226
[DOI] 10.1016/j.neuroscience.2018.02.025.
[PMID] 29555038.
2017
A single structurally conserved SUMOylation site in CRMP2 controls NaV1.7 function.
Channels (Austin, Tex.).
11(4):316-328
[DOI] 10.1080/19336950.2017.1299838.
[PMID] 28277940.
2017
CRISPR/Cas9 editing of Nf1 gene identifies CRMP2 as a therapeutic target in neurofibromatosis type 1-related pain that is reversed by (S)-Lacosamide.
Pain.
158(12):2301-2319
[DOI] 10.1097/j.pain.0000000000001002.
[PMID] 28809766.
2017
Dissecting the role of the CRMP2-neurofibromin complex on pain behaviors.
Pain.
158(11):2203-2221
[DOI] 10.1097/j.pain.0000000000001026.
[PMID] 28767512.
2017
Immunohistochemical Markers for Prospective Studies in Neurofibromatosis-1 Porcine Models.
The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.
65(10):607-618
[DOI] 10.1369/0022155417729357.
[PMID] 28846462.
2017
Long-lasting antinociceptive effects of green light in acute and chronic pain in rats.
Pain.
158(2):347-360
[DOI] 10.1097/j.pain.0000000000000767.
[PMID] 28092651.
2017
Sensitization of Ion Channels Contributes to Central and Peripheral Dysfunction in Neurofibromatosis Type 1.
Molecular neurobiology.
54(5):3342-3349
[DOI] 10.1007/s12035-016-9907-1.
[PMID] 27167129.
2017
Targeting a Potassium Channel/Syntaxin Interaction Ameliorates Cell Death in Ischemic Stroke.
The Journal of neuroscience : the official journal of the Society for Neuroscience.
37(23):5648-5658
[DOI] 10.1523/JNEUROSCI.3811-16.2017.
[PMID] 28483976.
2017
Transient Receptor Potential Vanilloid 1 Antagonists Prevent Anesthesia-induced Hypothermia and Decrease Postincisional Opioid Dose Requirements in Rodents.
Anesthesiology.
127(5):813-823
[DOI] 10.1097/ALN.0000000000001812.
[PMID] 28806222.
2016
(S)-Lacosamide Binding to Collapsin Response Mediator Protein 2 (CRMP2) Regulates CaV2.2 Activity by Subverting Its Phosphorylation by Cdk5.
Molecular neurobiology.
53(3):1959-1976
[DOI] 10.1007/s12035-015-9141-2.
[PMID] 25846820.
2016
(S)-lacosamide inhibition of CRMP2 phosphorylation reduces postoperative and neuropathic pain behaviors through distinct classes of sensory neurons identified by constellation pharmacology.
Pain.
157(7):1448-1463
[DOI] 10.1097/j.pain.0000000000000555.
[PMID] 26967696.
2016
Efficacy of (S)-Lacosamide in preclinical models of cephalic pain.
Pain reports.
1(1)
[PMID] 27917413.
2016
Hierarchical CRMP2 posttranslational modifications control NaV1.7 function.
Proceedings of the National Academy of Sciences of the United States of America.
113(52):E8443-E8452
[DOI] 10.1073/pnas.1610531113.
[PMID] 27940916.
2016
Neuronal networks in mental diseases and neuropathic pain: Beyond brain derived neurotrophic factor and collapsin response mediator proteins.
World journal of psychiatry.
6(1):18-30
[DOI] 10.5498/wjp.v6.i1.18.
[PMID] 27014595.
2016
Sustained relief of ongoing experimental neuropathic pain by a CRMP2 peptide aptamer with low abuse potential.
Pain.
157(9):2124-2140
[DOI] 10.1097/j.pain.0000000000000628.
[PMID] 27537210.
2015
A membrane-delimited N-myristoylated CRMP2 peptide aptamer inhibits CaV2.2 trafficking and reverses inflammatory and postoperative pain behaviors.
Pain.
156(7):1247-1264
[DOI] 10.1097/j.pain.0000000000000147.
[PMID] 25782368.
2015
Chimeric agents derived from the functionalized amino acid, lacosamide, and the α-aminoamide, safinamide: evaluation of their inhibitory actions on voltage-gated sodium channels, and antiseizure and antinociception activities and comparison with lacosamide and safinamide.
ACS chemical neuroscience.
6(2):316-30
[DOI] 10.1021/cn5002182.
[PMID] 25418676.
2015
Chimeric derivatives of functionalized amino acids and α-aminoamides: compounds with anticonvulsant activity in seizure models and inhibitory actions on central, peripheral, and cardiac isoforms of voltage-gated sodium channels.
Bioorganic & medicinal chemistry.
23(13):3655-66
[DOI] 10.1016/j.bmc.2015.04.014.
[PMID] 25922183.
2015
CRMP5 Controls Glioblastoma Cell Proliferation and Survival through Notch-Dependent Signaling.
Cancer research.
75(17):3519-28
[DOI] 10.1158/0008-5472.CAN-14-0631.
[PMID] 26122847.
2015
Specific binding of lacosamide to collapsin response mediator protein 2 (CRMP2) and direct impairment of its canonical function: implications for the therapeutic potential of lacosamide.
Molecular neurobiology.
51(2):599-609
[DOI] 10.1007/s12035-014-8775-9.
[PMID] 24944082.
2015
Tlx3 promotes glutamatergic neuronal subtype specification through direct interactions with the chromatin modifier CBP.
PloS one.
10(8)
[DOI] 10.1371/journal.pone.0135060.
[PMID] 26258652.
2014
Carbamazepine potentiates the effectiveness of morphine in a rodent model of neuropathic pain.
PloS one.
9(9)
[DOI] 10.1371/journal.pone.0107399.
[PMID] 25221944.
2014
Collapsin response mediator protein 2 (CRMP2) interacts with N-methyl-D-aspartate (NMDA) receptor and Na+/Ca2+ exchanger and regulates their functional activity.
The Journal of biological chemistry.
289(11):7470-82
[DOI] 10.1074/jbc.M113.518472.
[PMID] 24474686.
2014
Differential neuroprotective potential of CRMP2 peptide aptamers conjugated to cationic, hydrophobic, and amphipathic cell penetrating peptides.
Frontiers in cellular neuroscience.
8
[DOI] 10.3389/fncel.2014.00471.
[PMID] 25674050.
2014
Differential regulation of collapsin response mediator protein 2 (CRMP2) phosphorylation by GSK3ß and CDK5 following traumatic brain injury.
Frontiers in cellular neuroscience.
8
[DOI] 10.3389/fncel.2014.00135.
[PMID] 24904280.
2014
Identification of a functional interaction of HMGB1 with Receptor for Advanced Glycation End-products in a model of neuropathic pain.
Brain, behavior, and immunity.
42:169-77
[DOI] 10.1016/j.bbi.2014.06.199.
[PMID] 25014009.
2014
Social learning and amygdala disruptions in Nf1 mice are rescued by blocking p21-activated kinase.
Nature neuroscience.
17(11):1583-90
[DOI] 10.1038/nn.3822.
[PMID] 25242307.
2014
Substituted N-(biphenyl-4′-yl)methyl (R)-2-acetamido-3-methoxypropionamides: potent anticonvulsants that affect frequency (use) dependence and slow inactivation of sodium channels.
Journal of medicinal chemistry.
57(14):6165-82
[DOI] 10.1021/jm500707r.
[PMID] 25004277.
2014
The functionalized amino acid (S)-Lacosamide subverts CRMP2-mediated tubulin polymerization to prevent constitutive and activity-dependent increase in neurite outgrowth.
Frontiers in cellular neuroscience.
8
[DOI] 10.3389/fncel.2014.00196.
[PMID] 25104922.
2013
(Biphenyl-4-yl)methylammonium chlorides: potent anticonvulsants that modulate Na+ currents.
Journal of medicinal chemistry.
56(14):5931-9
[DOI] 10.1021/jm4007092.
[PMID] 23772678.
2013
Benzyloxybenzylammonium chlorides: Simple amine salts that display anticonvulsant activity.
Bioorganic & medicinal chemistry.
21(24):7655-62
[DOI] 10.1016/j.bmc.2013.10.031.
[PMID] 24238903.
2013
Challenging the catechism of therapeutics for chronic neuropathic pain: Targeting CaV2.2 interactions with CRMP2 peptides.
Neuroscience letters.
557 Pt A(0 0):27-36
[DOI] 10.1016/j.neulet.2013.06.057.
[PMID] 23831344.
2013
CHARACTERIZING CALCIUM INFLUX VIA VOLTAGE- AND LIGAND-GATED CALCIUM CHANNELS IN EMBRYONIC ALLIGATOR NEURONS IN CULTURE.
Translational neuroscience.
4(3)
[DOI] 10.2478/s13380-013-0132-3.
[PMID] 24260711.
2013
CRMP2 protein SUMOylation modulates NaV1.7 channel trafficking.
The Journal of biological chemistry.
288(34):24316-31
[DOI] 10.1074/jbc.M113.474924.
[PMID] 23836888.
2013
Discovery of lacosamide affinity bait agents that exhibit potent voltage-gated sodium channel blocking properties.
ACS chemical neuroscience.
4(3):463-74
[DOI] 10.1021/cn300188h.
[PMID] 23509982.
2013
Small-molecule inhibition of the uPAR·uPA interaction: synthesis, biochemical, cellular, in vivo pharmacokinetics and efficacy studies in breast cancer metastasis.
Bioorganic & medicinal chemistry.
21(7):2145-55
[DOI] 10.1016/j.bmc.2012.12.047.
[PMID] 23411397.
2013
SUMOylation alters CRMP2 regulation of calcium influx in sensory neurons.
Channels (Austin, Tex.).
7(3):153-9
[DOI] 10.4161/chan.24224.
[PMID] 23510938.
2013
Suppression of pain-related behavior in two distinct rodent models of peripheral neuropathy by a homopolyarginine-conjugated CRMP2 peptide.
Journal of neurochemistry.
124(6):869-79
[DOI] 10.1111/jnc.12070.
[PMID] 23106100.
2012
A PEPTIDE UNCOUPLING CRMP-2 FROM THE PRESYNAPTIC Ca(2+) CHANNEL COMPLEX DEMONSTRATES EFFICACY IN ANIMAL MODELS OF MIGRAINE AND AIDS THERAPY-INDUCED NEUROPATHY.
Translational neuroscience.
3(1):1-8
[PMID] 22662308.
2012
Cdk5-mediated phosphorylation of CRMP-2 enhances its interaction with CaV2.2.
FEBS letters.
586(21):3813-8
[DOI] 10.1016/j.febslet.2012.09.022.
[PMID] 23022559.
2012
CRMP-2 peptide mediated decrease of high and low voltage-activated calcium channels, attenuation of nociceptor excitability, and anti-nociception in a model of AIDS therapy-induced painful peripheral neuropathy.
Molecular pain.
8
[DOI] 10.1186/1744-8069-8-54.
[PMID] 22828369.
2012
Delayed calcium dysregulation in neurons requires both the NMDA receptor and the reverse Na+/Ca2+ exchanger.
Neurobiology of disease.
46(1):109-17
[DOI] 10.1016/j.nbd.2011.12.051.
[PMID] 22249110.
2012
Disruption of NMDAR-CRMP-2 signaling protects against focal cerebral ischemic damage in the rat middle cerebral artery occlusion model.
Channels (Austin, Tex.).
6(1):52-9
[DOI] 10.4161/chan.18919.
[PMID] 22373559.
2012
Identification of the benzyloxyphenyl pharmacophore: a structural unit that promotes sodium channel slow inactivation.
ACS chemical neuroscience.
3(12):1037-49
[DOI] 10.1021/cn300129d.
[PMID] 23259039.
2012
Ifenprodil, a NR2B-selective antagonist of NMDA receptor, inhibits reverse Na+/Ca2+ exchanger in neurons.
Neuropharmacology.
63(6):974-82
[DOI] 10.1016/j.neuropharm.2012.07.012.
[PMID] 22820271.
2012
Inhibition of transmitter release and attenuation of anti-retroviral-associated and tibial nerve injury-related painful peripheral neuropathy by novel synthetic Ca2+ channel peptides.
The Journal of biological chemistry.
287(42):35065-35077
[DOI] 10.1074/jbc.M112.378695.
[PMID] 22891239.
2012
Neuroexcitatory effects of morphine-3-glucuronide are dependent on Toll-like receptor 4 signaling.
Journal of neuroinflammation.
9
[DOI] 10.1186/1742-2094-9-200.
[PMID] 22898544.
2012
Opening Pandora’s jar: a primer on the putative roles of CRMP2 in a panoply of neurodegenerative, sensory and motor neuron, and central disorders.
Future neurology.
7(6):749-771
[PMID] 23308041.
2012
Regulation of CREB signaling through L-type Ca2+ channels by Nipsnap-2.
Channels (Austin, Tex.).
6(2):94-102
[DOI] 10.4161/chan.19415.
[PMID] 22627147.
2012
The persistent release of HMGB1 contributes to tactile hyperalgesia in a rodent model of neuropathic pain.
Journal of neuroinflammation.
9
[DOI] 10.1186/1742-2094-9-180.
[PMID] 22824385.
2011
Development and characterization of novel derivatives of the antiepileptic drug lacosamide that exhibit far greater enhancement in slow inactivation of voltage-gated sodium channels.
ACS chemical neuroscience.
2(2):90-106
[PMID] 21532923.
2011
Further insights into the antinociceptive potential of a peptide disrupting the N-type calcium channel-CRMP-2 signaling complex.
Channels (Austin, Tex.).
5(5):449-56
[DOI] 10.4161/chan.5.5.17363.
[PMID] 21829088.
2011
Merging Structural Motifs of Functionalized Amino Acids and α-Aminoamides Results in Novel Anticonvulsant Compounds with Significant Effects on Slow and Fast Inactivation of Voltage-gated Sodium Channels and in the Treatment of Neuropathic Pain.
ACS chemical neuroscience.
2(6):317-322
[PMID] 21765969.
2011
Neuroprotection against traumatic brain injury by a peptide derived from the collapsin response mediator protein 2 (CRMP2).
The Journal of biological chemistry.
286(43):37778-92
[DOI] 10.1074/jbc.M111.255455.
[PMID] 21832084.
2011
QUANTITATIVE RT-PCR ANALYSES OF FIVE EVOLUTIONARY CONSERVED GENES IN ALLIGATOR BRAINS DURING DEVELOPMENT.
Translational neuroscience.
2(4):339-343
[PMID] 22379598.
2011
Suppression of inflammatory and neuropathic pain by uncoupling CRMP-2 from the presynaptic Ca²⁺ channel complex.
Nature medicine.
17(7):822-9
[DOI] 10.1038/nm.2345.
[PMID] 21642979.
2011
Targeting multiple conformations leads to small molecule inhibitors of the uPAR·uPA protein-protein interaction that block cancer cell invasion.
ACS chemical biology.
6(11):1232-43
[DOI] 10.1021/cb200180m.
[PMID] 21875078.
2011
VOLTAGE-GATED CALCIUM CHANNELS ARE NOT AFFECTED BY THE NOVEL ANTI-EPILEPTIC DRUG LACOSAMIDE.
Translational neuroscience.
2(1):13-22
[PMID] 21949591.
2010
ALTERED CALCIUM CURRENTS AND AXONAL GROWTH IN Nf1 HAPLOINSUFFICIENT MICE.
Translational neuroscience.
1(2):106-114
[PMID] 21949590.
2010
Emerging roles of collapsin response mediator proteins (CRMPs) as regulators of voltage-gated calcium channels and synaptic transmission.
Communicative & integrative biology.
3(2):172-5
[PMID] 20585514.
2010
In silico docking and electrophysiological characterization of lacosamide binding sites on collapsin response mediator protein-2 identifies a pocket important in modulating sodium channel slow inactivation.
The Journal of biological chemistry.
285(33):25296-307
[DOI] 10.1074/jbc.M110.128801.
[PMID] 20538611.
2009
An atypical role for collapsin response mediator protein 2 (CRMP-2) in neurotransmitter release via interaction with presynaptic voltage-gated calcium channels.
The Journal of biological chemistry.
284(45):31375-90
[DOI] 10.1074/jbc.M109.009951.
[PMID] 19755421.
2009
Regulation of N-type voltage-gated calcium channels (Cav2.2) and transmitter release by collapsin response mediator protein-2 (CRMP-2) in sensory neurons.
Journal of cell science.
122(Pt 23):4351-62
[DOI] 10.1242/jcs.053280.
[PMID] 19903690.
2007
A proteomic screen for presynaptic terminal N-type calcium channel (CaV2.2) binding partners.
Journal of biochemistry and molecular biology.
40(3):302-14
[PMID] 17562281.
2007
Munc18: a presynaptic transmitter release site N type (CaV2.2) calcium channel interacting protein.
Channels (Austin, Tex.).
1(1):11-20
[PMID] 19170253.
2007
The presynaptic CaV2.2 channel-transmitter release site core complex.
The European journal of neuroscience.
26(3):547-59
[PMID] 17686036.
2007
The transmitter release-site CaV2.2 channel cluster is linked to an endocytosis coat protein complex.
The European journal of neuroscience.
26(3):560-74
[PMID] 17686037.
Grants
Feb 2025
ACTIVE
Dissection of NTSR2/calcium channel signaling as a non-opioid spinal analgesic mechanism for the treatment of high impact chronic pain
Role: Principal Investigator
Funding: UNIV OF TEXAS SW MEDICAL CENTER
via NATL INST OF HLTH
Jan 2025
ACTIVE
Targeting CRMP2-Nav1.7 and Cav2.2 interaction for fibromyalgia treatment
Role: Other
Funding: PHARMA RES AND MANUFACTURERS OF AMERICA
Sep 2024
ACTIVE
Targeting Schwann cell dysfunction and repair signaling in chemotherapy induced painful peripheral neuropathy
Role: Principal Investigator
Funding: NEW YORK UNIV
via NATL INST OF HLTH NIDCR
Sep 2024
ACTIVE
Validation of a Nonopioid Analgesic Pathway in Human Sensory Ganglia and Spinal Cord
Role: Principal Investigator
Funding: US ARMY MED RES ACQUISITION
Sep 2024
ACTIVE
Neuropeptide Y1 Receptor-Expressing Neurons in the Lateral Parabrachial Nucleus in Neuropathic Pain
Role: Other
Funding: NATL INST OF HLTH NINDS
Sep 2024
ACTIVE
Antagonists of CRMP2 Phosphorylation for Chemotherapy-Induced Peripheral Neuropathy
Role: Principal Investigator
Funding: NATL INST OF HLTH NINDS
Jan 2024
ACTIVE
Endosomal mechanisms signaling oral cancer pain
Role: Principal Investigator
Funding: NEW YORK UNIV
via NATL INST OF HLTH NIDCR
Jan 2024
ACTIVE
Validation of Neuropilin-1 Receptor Signaling in Nociceptive Processing
Role: Principal Investigator
Funding: NATL INST OF HLTH NINDS
Jan 2024
ACTIVE
Lymphocyte Antigen 6 (Ly6) Proteins: New Players in Chronic Pain
Role: Other
Funding: NATL INST OF HLTH NINDS
Jan 2024
ACTIVE
Validation of Spinal Neurotensin Receptor 2 as an Analgesic Target
Role: Principal Investigator
Funding: UNIV OF TEXAS SW MEDICAL CENTER
via NATL INST OF HLTH NINDS
Jan 2024
ACTIVE
Genetic and Pharmacological Validation of CRMP2 Phosphorylation as a Novel therapeutic Target for Neuropathic Pain
Role: Principal Investigator
Funding: NATL INST OF HLTH NINDS
Contact Details
Phones:
- Business:
- (520) 271-0433
Emails:
- Business:
- r.khanna@ufl.edu
Addresses:
- Business Mailing:
-
L4-177
1149 Newell Drive
GAINESVILLE FL 32610 - Business Street:
-
PO Box 100267
GAINESVILLE FL 32610